CURRICULUM VITAE DR. ROBERTA FAZIO
EUROPEAN FORMAT

CURRENT POSITION

Title:	**Medical Oncologist**
Department:	Medical Oncology, Gastrointestinal Unit
Institution:	**IRCSS Istituto Nazionale dei Tumori**
Address:	Via Giacomo Venezian, 1, 20133, Milan - Italy
Start date:	01.12.2024

PREVIOUS WORKING EXPERIENCES

Period:	From 04.11.2019 to 11.11.2024
Position:	**Medical Oncology Resident**
Institution:	**IRCSS Humanitas Research Hospital**
Address:	Via Alessandro Manzoni, 56, 20089, Rozzano (Milan) - Italy
Period:	From 01.02.2023 to 31.01.2024
Position:	**Medical Research Fellow**
Institution:	**Institut Jules Bordet, Department of Digestive Oncology**
Address:	Rue Meylemeersch, 1070, Anderlecht (Bruxelles) - Belgium

PROFESSIONAL REGISTRATIONS

Period:	From 01.03.2019
Council:	**College of Physicians, Palermo (Italy)**
Type of registration:	Full registration with a licence to practise

QUALIFICATIONS

Qualification:	**Medical Oncologist**
Year:	2024
Institution:	IRCCS Humanitas Research Hospital, Rozzano (Milan)- Italy
Qualification:	**Diploma in Medicine and Surgery**
Year:	2018
Institution:	University of Palermo - Italy

EDUCATION

Period:	From November 2019 to November 2024
Institution:	**Humanitas Research Hospital - Italy**
Degree/Qualification:	**Medical Oncology Resident**
Mark:	70 cum laude/70
Period:	From September 2016 to February 2017
Institution:	**Coimbra University - Portugal**
Degree/Qualification:	**Visiting Scholar (Erasmus+ fellowship)**
Mark:	Not applicable
Period:	From 2012 to 2018
Institution:	**University of Palermo - Italy**
Degree/Qualification:	**Bachelor of Medicine, Bachelor of Surgery**
Mark:	110 cum laude/110

Period:	From 2007 to 2012
Institution:	**State Classical High School "Giuseppe Garibaldi", Palermo –Italy**
Degree/Qualification:	**Classical High-School Diploma**
Mark:	100 cum laude/100

PROFESSIONAL TASKS

First language:	Italian (native speaker)
Other languages:	English (fluent written/spoken) Portuguese *(*basic communication skills) French (basic communication skills)
Technical knowledge:	Excellent knowledge of Microsoft Office Suite (Word, Excel, PowerPoint). Excellent knowledge of Microsoft Windows Excellent knowledge of use of software for clinical activities.

PUBLICATIONS

- Zucali PA, ...**Fazio R** et al. Advances in drug treatment for mesothelioma. Expert Opinion on Pharmacotherapy, 2022; 23:8, 929-946.
- **Fazio R**, Grimaudo MS, Laffi A et al. How To Develop an Adolescent and Young Adult Program in an Adult Cancer Center: the Humanitas Research Hospital Experience. CTOS Annual Meeting 2022 (poster presentation, P117).
- Grimaudo MS, Laffi A, Gennaro N, **Fazio R**, D'Orazio F, et al. Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule. Front. Oncol. 2023; 13:119012.
- Perrino M, Cordua N, De Vincenzo F, Borea F,...**Fazio R**, et al. Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy. Cancers 2023,15,5574.
- Assaf I, Fimereli D, Anthoine G, Fazio R, Daprà V, et al. Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer. Cancers 2023, 15, 5823.
- Audisio A, **Fazio R**, Hendlisz A, Sclafani F. Neoadjuvant chemotherapy for resectable colon cancer in the era of precision oncology: a step forward or a step back? Curr. Opin. Oncol. 2023; 35(4):p 315-317
- Daprà V, Airoldi M, Bartolini M, **Fazio R**, Mondello G, et al. Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand? Int. J. Mol. Sci. 2023, 24, 12159.
- Audisio A, **Fazio R**, Dapra` V, Assaf I, et al. Neoadjuvant chemotherapy for early-stage colon cancer. Cancer Treatment Reviews. 2024;123, 102676.
- **Fazio R**, Arnold D, Folprecht G, et al. Highlights from the ESMO Annual Meeting 2023 e EORTC GI Tract Group picks from the colorectal and anal cancer track. ESMO Gastrointestinal Oncology, 2024.
- Perrino M, Voulaz E, Balin S, ...**Fazio R**...and Mavilio D. Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs. Front. Immunol. 2024 15:1288045.
- Stucchi E, Bartolini M, Airoldi M, **Fazio R,** et al. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? Expert Opin Pharmacother.2024 Apr 3:1-12.
- Sur D, Coroama CI, Audisio A, **Fazio R** et al. Clinical Outcome of Colorectal Cancer Patients with Concomitant Hypertension: A Systematic Review and Meta-Analysis. J. Pers. Med. 2024, 14, 520.
- **Fazio R** et al. Current trends of clinical trials for older patients with cancer: A systematic review. ASCO 2024 poster presentation (Care Delivery/Models of Care session). JCO (2024) 42, 1621-1621.
- **Fazio R,** Audisio A, Daprà V, et al. Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI- H gastrointestinal cancers. Cancer Treat Rev. 2024 Jul;128:102752.
- Airoldi M, Bartolini M, **Fazio R,** et al. First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy? Curr Oncol Rep. 2024 Nov;26(11):1489-1501.
- **Fazio R** et al. State of the art of gastrointestinal (GI) cancer trials for older patients (pts): A systematic review (SR) Poster presentation at ESMO GI 2024. Annals of Oncology, 2024, Volume 35, S201 - S202.
- **Fazio R** et al. Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial. ESMO Open. 2025 Jul;10(7):105329.
- **Fazio R** et al. Reply letter to comments on: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial. ESMO Open . 2025 Jul;10(7):105329.
- **Fazio R** et al. Clinical trials for older cancer patients: A systematic review. Cancer Treat Rev. 2025 Nov 4:141:103045.

- **Fazio R** et al. Real world-data on neoadjuvant/definitive immunotherapy (IO) or chemo-immunotherapy (CT-IO) in patients (pts) with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) resectable or potentially resectable gastric/gastroesophageal junction (GEJ) carcinoma. Annals of Oncology, Volume 36, S1204 - S1205. ESMO congress 2025 poster presentation.
- Antoniotti C...**Fazio R**...et al. FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient databased pooled analysis of randomized trials. European Journal of Cancer, 2025, Volume 228, 115713.
- **Fazio R** et al. Early- and advanced-stage MSI-H non-colorectal cancers: best management and challenges in 2025. ESMO Gastrointestinal Oncology. 2026, Volume 11, 100296.
- Conca V,...**Fazio R,** et al. Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study. Journal of Clinical Oncology, 2026.
- Manca P,...**Fazio R**,...et al. CtDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial. Clin Cancer Res. 2026; OF1–OF11.
- A. Raimondi,...**Fazio R,**…et al. Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery 1/2 Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis. J Clin Oncol 2026; 43:3457-3467.
- **Fazio R** al et. Survival outcomes according to ramucirumab (RAM)-related hypertension (HTN) inpatients (pts) with advanced HER2-negative gastric (G) or gastro-esophageal junction(GEJ) cancer: an exploratory analysis of the phase III ARMANI trial. J Clin Oncol 44, 4051(2026). ASCO 2026 poster presentation (Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary session).